23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Metabolic syndrome Patient sample and mouse studies suggest AHR agonists could help treat metabolic syndrome. In patient fecal samples, levels of endogenous AHR ligands -- including indole, indole acetic acid, 3-methylindole and tryptamine --...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
16:58 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round on March 15 led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche...
00:20 , Mar 16, 2018 |  BioCentury  |  Finance

Following its blueprint

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round. Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors led...
11:55 , Mar 15, 2018 |  BC Extra  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche Venture Fund, Boxer...
21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the...
20:51 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

On Dec. 14, immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while...
20:49 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
11:57 , Dec 14, 2017 |  BC Extra  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

Immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while Kyn disclosed...
18:40 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Insomnia Mouse studies suggest inhibiting ARNTL could help treat tuberous sclerosis complex (TSC)-associated sleep disorder. In cortical tissue samples from a mouse model of TSC, levels of ARNTL were higher and varied less with circadian...